Neuair Airmaster (Fluticasone Propionate, Salmeterol)

Neuair Airmaster is indicated for long‑term maintenance treatment of airway diseases that involve chronic inflammation and bronchoconstriction.

• Asthma: improves symptom control and reduces the frequency of exacerbations in patients requiring both anti‑inflammatory and bronchodilator therapy.
• Chronic obstructive pulmonary disease (COPD): helps maintain lung function and decreases the risk of COPD flare‑ups when used as part of a regular treatment regimen.

• Fluticasone propionate binds to glucocorticoid receptors in airway cells, suppressing inflammatory gene expression and reducing cytokine production. Salmeterol selectively stimulates β2‑adrenergic receptors on bronchial smooth muscle, leading to prolonged relaxation and bronchodilation. The combined action provides both anti‑inflammatory and sustained bronchodilatory effects, improving airway patency over time.

Neuair Airmaster may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Oral candidiasis: fungal infection of the mouth or throat.
• Hoarseness or dysphonia: voice changes due to local irritation.
• Throat irritation or cough: discomfort after inhalation.
• Headache: mild to moderate intensity.
• Nasal congestion: blockage or runny nose.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing.
• Adrenal suppression: reduced cortisol production with prolonged high‑dose use.
• Immune system effects: increased susceptibility to infections.
• Cardiac arrhythmias: irregular heart rhythms, especially with high β2‑agonist exposure.
• Hypersensitivity reactions: rash, swelling, or anaphylaxis.
• Osteoporosis: decreased bone mineral density with long‑term corticosteroid exposure.

Before prescribing Neuair Airmaster, clinicians should consider several safety aspects.

• Assess infection risk: monitor for signs of oral thrush or respiratory infections.
• Evaluate growth in children: prolonged corticosteroid exposure may affect growth velocity.
• Review cardiovascular status: patients with arrhythmias should be observed closely.
• Consider drug interactions: avoid concurrent use of strong CYP3A4 inhibitors without dose adjustment.
• Monitor for adrenal insufficiency: especially after abrupt discontinuation of high doses.
• Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture and direct sunlight.

Neuair Airmaster can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure to fluticasone.
• Non‑selective β‑blockers (e.g., propranolol): can blunt the bronchodilator effect of salmeterol.
• Monoamine oxidase inhibitors (MAOIs): may increase the risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely)

• Diuretics (e.g., furosemide): may enhance hypokalemia when combined with β2‑agonists.
• Theophylline: concurrent use can increase the risk of tachyarrhythmias.
• Ritonavir: may raise fluticasone levels, requiring clinical monitoring.